Inhibrx Biosciences Inc. (INBX) vs Kardigan, Inc. (KARD)
A side-by-side comparison of Inhibrx Biosciences Inc. and Kardigan, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
INBX
Inhibrx Biosciences Inc.
$94.38HealthcareDelayed quote: Oct 6, 2026, 2:45 PM EDT
KARD
Kardigan, Inc.
$14.13HealthcareDelayed quote: Oct 6, 2026, 2:45 PM EDT
Total return — INBX vs KARD
growth of $100 · dividends reinvested · last 1yINBX +0.4% (+0.4%/yr)KARD -30.7% (-30.7%/yr)INBX compounded faster over this window
INBX KARD
INBX vs KARD: by the numbers
- •INBX is the larger company ($1.38B vs $1.26B market cap).
- •Both run net losses; KARD's is the smaller (0.00% vs -10773.46% net margin).
Metrics side by side
Valuation
| Metric | INBX | KARD |
|---|---|---|
| P/B ratio | N/A | 2.05 |
Profitability
| Metric | INBX | KARD |
|---|---|---|
| Gross margin | -91.00% | 0.00% |
| Operating margin | -10386.54% | 0.00% |
| Net margin | -10773.46% | 0.00% |
| ROIC | -99.35% | -57.11% |
Growth (annualized)
| Metric | INBX | KARD |
|---|---|---|
| Total return CAGR (5Y) | 27.64% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.